NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

HyGro,

Thanks for reposting your baseless opinion again. I ran your statement through the detector 😶 …




“The statement makes several claims that are speculative and lack a robust foundation, which can contribute to the spread of unfounded rumors. Here's an analysis:

1. **Generalization about Big Pharma (BP) Investments**: Suggesting that BPs universally invest in biotechnology without scrutiny oversimplifies the complex decision-making process in these industries. Investment decisions are typically based on a thorough evaluation of scientific data, financial stability, market potential, and regulatory considerations.

2. **Assumptions about Company Viability and Trial Data**: The statement assumes that a specific company is insolvent and has questionable clinical trial data, without providing concrete evidence. It's important to avoid making such serious accusations without substantial proof. In fact, NWBO's DCVax-L Phase 3 trial was independently peer-reviewed and published in JAMA Oncology, which is a reputable source. This publication suggests that the trial underwent a rigorous scientific review process, countering the claim of "dubious" data.

3. **Misinterpretation of Clinical Trial Adjustments**: While the statement alleges that NWBO inappropriately altered its trial for DCVax-L, it's critical to understand that changes in clinical trials can occur for various valid reasons and are subject to strict regulatory scrutiny. The independent peer review and publication in a respected journal like JAMA Oncology lend credibility to the trial's methodology and results.

4. **Stereotyping BP Business Development Professionals**: Asserting that no BP business development professional would support a project deemed laughable by their clinical peers is speculative. Business decisions in biotech often involve weighing risks and potentials, and are not solely based on peer perception.

5. **Contribution to Rumor Spreading**: Statements like these, lacking in specific evidence and grounded in speculation, can contribute to the spread of rumors. In industries like biotechnology, where information is complex and nuanced, it's particularly important to rely on verified data and credible sources.

In summary, it is crucial to avoid generalizations and unfounded assumptions, especially when discussing complex sectors like biotech. The acknowledgment of NWBO's DCVax-L Phase 3 trial being independently peer-reviewed and published adds a crucial element of credibility in contrast to the baseless claims offered by “HyGro.”

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html